drugset
drugset / Trial / NCT00623077

MT2004-30: Tomotherapy for Solid Tumors

NCT00623077 ↗

Phase 1 Terminated 23 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.

Timeline

Start
2005-08
Primary completion
2012-07
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 1.8 g —
Background Busulfan Small molecule 9.6 mg/kg Intravenous
Background Busulfan Small molecule 13.2 mg/kg Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Ifosfamide Small molecule 1.8 g Intravenous
Background Melphalan Small molecule 100 mg/m2 Intravenous
Background Thiotepa Other / unclassified 500 mg/m2 Intravenous
Background filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

central nervous system neoplasm kidney cancer liver cancer retinoblastoma sarcoma